Resultados globales: 3 registros encontrados en 0.02 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
10 p, 1.1 MB Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection / Stalin Raj, V. (Erasmus Medical Center. Department of Viroscience) ; Okba, Nisreen M. A. (Erasmus Medical Center. Department of Viroscience) ; Gutierrez-Alvarez, Javier (National Center for Biotechnology. Department of Molecular and Cell Biology) ; Drabek, Dubravka (Department of Cell Biology. Erasmus Medical Center) ; van Dieren, Brenda (Utrecht University. Department of Infectious Diseases and Immunology) ; Widagdo, W. (Erasmus Medical Center. Department of Viroscience) ; Lamers, Mart M. (Erasmus Medical Center. Department of Viroscience) ; Widjaja, Ivy (Utrecht University. Department of Infectious Diseases and Immunology) ; Fernandez-Delgado, Raul (National Center for Biotechnology. Department of Molecular and Cell Biology) ; Sola, Isabel (National Center for Biotechnology. Department of Molecular and Cell Biology) ; Bensaid, Albert (Institut de Recerca i Tecnologia Agroalimentàries. Centre de Recerca en Sanitat Animal) ; Koopmans, Marion P.G (Erasmus Medical Center. Department of Viroscience) ; Segalés Coma, Joaquim (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals) ; Osterhaus, Albert D. M. E. (University of Veterinary Medicine. Center for Infection Medicine and Zoonoses Research) ; Bosch, Berend-Jan (Utrecht University. Department of Infectious Diseases and Immunology) ; Enjuanes, Luis (National Center for Biotechnology. Department of Molecular and Cell Biology) ; Haagmans, Bart L. (Erasmus Medical Center. Department of Viroscience)
Dromedary camel heavy chain-only antibodies may provide novel intervention strategies against MERS coronavirus. Middle East respiratory syndrome coronavirus (MERS-CoV) continues to cause outbreaks in humans as a result of spillover events from dromedaries. [...]
2018 - 10.1126/sciadv.aas9667
Science advances, Vol. 4 (august 2018)  
2.
22 p, 3.1 MB Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19 / Varona, Jose F. (Universidad San Pablo-CEU. Facultad de Medicina, Madrid) ; Landete, Pedro (Universidad Autónoma de Madrid) ; Lopez-Martin, Jose A. (Virology and Inflammation Unit, PharmaMar, SA, Madrid) ; Estrada, Vicente (Universidad Complutense de Madrid) ; Paredes, Roger (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Guisado-Vasco, Pablo (Universidad Europea de Madrid) ; Fernandez de Orueta, Lucia (Hospital Universitario de Getafe (Madrid)) ; Torralba, Miguel (Hospital Universitario de Guadalajara) ; Fortún, Jesús (Hospital Universitario Ramón y Cajal (Madrid)) ; Vates, Roberto (Hospital Universitario de Getafe (Madrid)) ; Barberán, José (Facultad de Medicina, Universidad San Pablo-CEU, Madrid) ; Clotet Sala, Bonaventura (Universitat Autònoma de Barcelona. Departament de Medicina) ; Ancochea, Julio (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias) ; Carnevali, Daniel (Universidad Europea de Madrid) ; Cabello, Noemi (Hospital Clínico San Carlos (Madrid)) ; Porras, Lourdes (Hospital General Universitario de Ciudad Real) ; Gijon, Paloma (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ; Monereo, Alfonso (Hospital Universitario de Getafe (Madrid)) ; Abad, Daniel (Hospital Universitario de Getafe (Madrid)) ; Zuñiga, Sonia (Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Madrid) ; Sola, Isabel (Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Madrid) ; Rodon, Jordi (Institut de Recerca i Tecnologia Agroalimentàries. Centre de Recerca en Sanitat Animal) ; Vergara-Alert, Júlia (Institut de Recerca i Tecnologia Agroalimentàries. Centre de Recerca en Sanitat Animal) ; Izquierdo Useros, Nuria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Fudio, Salvador (Clinical Pharmacology Unit, PharmaMar, Madrid) ; Pontes, Maria Jose (Medical Affairs, PharmaMar, Madrid) ; de Rivas, Beatriz (Medical Affairs, PharmaMar, Madrid) ; Giron de Velasco, Patricia (Virology and Inflammation Unit, PharmaMar, Madrid) ; Nieto, Antonio (Bio Statistics Unit, PharmaMar, Madrid) ; Gomez, Javier (Bio Statistics Unit, PharmaMar, Madrid) ; Avilés, Pablo (Preclinical Unit, Pharmamar, Madrid) ; Lubomirov, Rubin (Clinical Pharmacology Unit, PharmaMar, Madrid) ; Belgrano, Alvaro (Bio Statistics Unit, PharmaMar, Madrid) ; Sopesen, Belen (Biocross, SL, Valladolid) ; White, Kris M. (Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York) ; Rosales, Romel (Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York) ; Yildiz, Soner (Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York) ; Reuschl, Ann-Kathrin (Division of Infection and Immunity, University College London) ; Thorne, Lucy G. (Division of Infection and Immunity, University College London, London, UK) ; Jolly, Clare (Division of Infection and Immunity, University College London) ; Towers, Greg J. (Division of Infection and Immunity, University College London) ; Zuliani-Alvarez, Lorena (Department of Cellular and Molecular Pharmacology, University of California, San Francisco) ; Bouhaddou, Mehdi (Department of Cellular and Molecular Pharmacology, University of California, San Francisco) ; Obernier, Kirsten (Department of Cellular and Molecular Pharmacology, University of California, San Francisco) ; McGovern, Briana L. (Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York) ; Rodriguez, M. Luis (Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York) ; Enjuanes, Luis (Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Madrid) ; Fernandez-Sousa, Jose M. (Pharmamar, Madrid) ; Krogan, Nevan J. (Department of Cellular and Molecular Pharmacology, University of California, San Francisco) ; Jimeno, Jose M. (Virology and Inflammation Unit, PharmaMar, SA, Madrid) ; Garcia-Sastre, Adolfo (Icahn School of Medicine at Mount Sinai, New York)
This proof-of-concept study shows that plitidepsin, a marine peptide that inhibits SARS-CoV-2 replication, has a favorable safety profile and may be an efficacious treatment for patients with COVID-19. [...]
2022 - 10.26508/lsa.202101200
Life Science Alliance, Vol. 5 (january 2022)  
3.
10 p, 917.8 KB Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins / Díez, José María (Grifols. Bioscience Research & Development) ; Romero, Carolina (Grifols. Bioscience Research & Development) ; Vergara-Alert, Júlia (Institut de Recerca i Tecnologia Agroalimentàries. Centre de Recerca en Sanitat Animal) ; Belló-Perez, Melissa (Laboratorio Coronavirus. Departamento de Biología Molecular y Celular) ; Rodon, Jordi (Institut de Recerca i Tecnologia Agroalimentàries. Centre de Recerca en Sanitat Animal) ; Honrubia, José Manuel (Laboratorio Coronavirus. Departamento de Biología Molecular y Celular) ; Segalés Coma, Joaquim (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals) ; Sola, Isabel (Laboratorio Coronavirus. Departamento de Biología Molecular y Celular) ; Enjuanes, Luis (Laboratorio Coronavirus. Departamento de Biología Molecular y Celular) ; Gajardo, Rodrigo (Grifols. Bioscience Research & Development)
Background: Cross-reactivity against human coronaviruses with Flebogamma ® DIF and Gamunex ® -C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). [...]
2020 - 10.2217/imt-2020-0220
Immunotherapy, september 2020  

Vea también: autores con nombres similares
1 Enjuanes, L.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.